• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2016;15(9):660. https://doi.org/10.1038/nrd.2016.178. This review summarizes the appoach to development of oncolytic viruses for cancer therapy.

Article  PubMed  PubMed Central  Google Scholar 

Zheng M, Huang J, Tong A, Yang H. Oncolytic viruses for cancer therapy: barriers and recent advances. Mol Ther Oncolytics. 2019;15:234–47. https://doi.org/10.1016/j.omto.2019.10.007.

Article  PubMed  PubMed Central  Google Scholar 

Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther. 2009;20(10):1119–32. https://doi.org/10.1089/hum.2009.135.

Article  PubMed  PubMed Central  Google Scholar 

Di Paolo NC, Miao EA, Iwakura Y, Murali-Krishna K, Aderem A, Flavell RA, Papayannopoulou T, Shayakhmetov DM. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity. 2009;31(1):110–21. https://doi.org/10.1016/j.immuni.2009.04.015.

Article  PubMed  PubMed Central  Google Scholar 

Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D. The advent of oncolytic virotherapy in oncology: the Rigvir(R) story. Eur J Pharmacol. 2018;837:117–26. https://doi.org/10.1016/j.ejphar.2018.08.042.

Article  PubMed  Google Scholar 

Liang M. Oncorine, the World First Oncolytic Virus Medicine and its Update in China. Curr Cancer Drug Targets. 2018;18(2):171–6. https://doi.org/10.2174/1568009618666171129221503.

Article  PubMed  Google Scholar 

Zeng J, Li X, Sander M, Zhang H, Yan G, Lin Y. Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas. Front Immunol. 2021;12:721830. https://doi.org/10.3389/fimmu.2021.721830.

Article  PubMed  PubMed Central  Google Scholar 

• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8. https://doi.org/10.1200/JCO.2014.58.3377. This trial presented data to support FDA approval of talimogene laherparevec for the treatment of advanced melanoma.

Article  PubMed  Google Scholar 

• Ekeke CN, Russell KL, Joubert K, Bartlett DL, Luketich JD, Soloff AC, Guo ZS, Lotze MT, Dhupar R. Fighting fire with fire: oncolytic virotherapy for thoracic malignancies. Ann Surg Oncol. 2021;28(5):2715–27. https://doi.org/10.1245/s10434-020-09477-4. This articles describes the approach to development of oncolytic viruses for the treatment of lung cancer.

Article  PubMed  PubMed Central  Google Scholar 

Bai Y, Hui P, Du X, Su X. Updates to the antitumor mechanism of oncolytic virus. Thorac Cancer. 2019;10(5):1031–5. https://doi.org/10.1111/1759-7714.13043.

Article  PubMed  PubMed Central  Google Scholar 

Matsuda T, Karube H, Aruga A. A comparative safety profile assessment of oncolytic virus therapy based on clinical trials. Ther Innov Regul Sci. 2018;52(4):430–7. https://doi.org/10.1177/2168479017738979.

Article  PubMed  Google Scholar 

Macedo N, Miller DM, Haq R, Kaufman HL. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer. 2020;8(2). https://doi.org/10.1136/jitc-2020-001486.

Wang Y, Zhou X, Wu Z, Hu H, Jin J, Hu Y, Dong Y, Zou J, Mao Z, Shi X, Huo Y, Lyu J, Fang Z, Zhang W, Zhu Y, Li B, Liu B. Preclinical safety evaluation of oncolytic herpes simplex virus type 2. Hum Gene Ther. 2019;30(5):651–60. https://doi.org/10.1089/hum.2018.170.

Article  PubMed  Google Scholar 

Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, Kuo H, Saddekni S, Stockard CR, Grizzle WE, Harris RD, Aurigemma R, Curiel DT, Alvarez RD. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res. 2010;16(21):5277–87. https://doi.org/10.1158/1078-0432.CCR-10-0791.

Article  PubMed  PubMed Central  Google Scholar 

Wei N, Fan JK, Gu JF, He LF, Tang WH, Cao X, Liu XY. A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy. Biochem Biophys Res Commun. 2009;388(2):234–9. https://doi.org/10.1016/j.bbrc.2009.07.142.

Article  PubMed  Google Scholar 

Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–62. https://doi.org/10.1038/nrd4663.

Article  PubMed  PubMed Central  Google Scholar 

Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373–9. https://doi.org/10.1111/cas.13027.

Article  PubMed  PubMed Central  Google Scholar 

Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 2014;4:74. https://doi.org/10.3389/fonc.2014.00074.

Article  PubMed  PubMed Central  Google Scholar 

Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, Freeman GJ, Ritz J. Interferon-gamma-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015;4(6):e1008824. https://doi.org/10.1080/2162402X.2015.1008824.

Article  PubMed  PubMed Central  Google Scholar 

Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunelliere J, Bramson JL, Lichty BD, Wan Y. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther. 2010;18(8):1430–9. https://doi.org/10.1038/mt.2010.98.

Article  PubMed  PubMed Central  Google Scholar 

Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tahtinen S, Oksanen M, Heiskanen R, Pesonen S, Joensuu T, Alanko T, Partanen K, Laasonen L, Kairemo K, Pesonen S, Kangasniemi L, Hemminki A. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013;19(10):2734–44. https://doi.org/10.1158/1078-0432.CCR-12-2546.

Article  PubMed  Google Scholar 

Woller N, Gurlevik E, Fleischmann-Mundt B, Schumacher A, Knocke S, Kloos AM, Saborowski M, Geffers R, Manns MP, Wirth TC, Kubicka S, Kuhnel F. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol Ther. 2015;23(10):1630–40. https://doi.org/10.1038/mt.2015.115.

Article  PubMed  PubMed Central  Google Scholar 

Reale A, Vitiello A, Conciatori V, Parolin C, Calistri A, Palu G. Perspectives on immunotherapy via oncolytic viruses. Infect Agent Cancer. 2019;14:5. https://doi.org/10.1186/s13027-018-0218-1.

Article  PubMed  PubMed Central  Google Scholar 

Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252(5007):854–6. https://doi.org/10.1126/science.1851332.

Article  PubMed  Google Scholar 

Pikor LA, Bell JC, Diallo JS. Oncolytic viruses: exploiting cancer’s deal with the devil. Trends Cancer. 2015;1(4):266–77. https://doi.org/10.1016/j.trecan.2015.10.004.

Article  PubMed  Google Scholar 

Shi T, Song X, Wang Y, Liu F, Wei J. Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment. Front Immunol. 2020;11:683. https://doi.org/10.3389/fimmu.2020.00683.

Article  PubMed  PubMed Central  Google Scholar 

Wang LC, Lynn RC, Cheng G, Alexander E, Kapoor V, Moon EK, Sun J, Fridlender ZG, Isaacs SN, Thorne SH, Albelda SM. Treating tumors with a vaccinia virus expressing IFNbeta illustrates the complex relationships between oncolytic ability and immunogenicity. Mol Ther. 2012;20(4):736–48. https://doi.org/10.1038/mt.2011.228.

Article  PubMed  Google Scholar 

Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res. 2009;69(19):7713–20. https://doi.org/10.1158/0008-5472.CAN-09-1013.

Article  PubMed  PubMed Central  Google Scholar 

Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, Ho M, Pastan I, Machuzak M, Benedict W, Zhang XQ, Lord EM, Litzky LA, Heitjan DF, June CH, Kaiser LR, Vonderheide RH, Albelda SM, Kanther M. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res. 2007;13(15 Pt 1):4456–66. https://doi.org/10.1158/1078-0432.CCR-07-0403.

Article  PubMed  Google Scholar 

Corke L, Sacher A. New strategies and combinations to improve outcomes in immunotherapy in metastatic non-small-cell lung cancer. Curr Oncol. 2021;29(1):38–55. https://doi.org/10.3390/curroncol29010004.

Article  PubMed  PubMed Central  Google Scholar 

Zhang H, Xie W, Zhang Y, Dong X, Liu C, Yi J, Zhang S, Wen C, Zheng L, Wang H. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. Cancer Gene Ther. 2021. https://doi.org/10.1038/s41417-021-00389-3.

Article  PubMed  PubMed Central  Google Scholar 

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-19 e10. https://doi.org/10.1016/j.cell.2017.08.027.

Article  PubMed  PubMed Central  Google Scholar 

Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol. 1997;71(6):4736–43. https://doi.org/10.1128/JVI.71.6.4736-4743.1997.

Article  PubMed  PubMed Central  Google Scholar 

Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y, Okazaki T, Marumoto T, Takahashi A, Takayama K, Nakanishi Y, Shimizu H, Tani K. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72(10):2609–21. https://doi.org/10.1158/0008-5472.CAN-11-3185.

Article  PubMed